Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

17.71 +0.19 (+1.08%)
Streaming Delayed Price Updated: 1:13 PM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 621,493
Open 16.55
Bid (Size) 17.67 (200)
Ask (Size) 17.71 (400)
Prev. Close 17.52
Today's Range 16.55 - 18.14
52wk Range 6.255 - 20.76
Shares Outstanding 144,311,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization
Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that... 
Via MarketMinute
News headline image
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
Full year MRD revenue growth of 46% driven by clonoSEQ® testing volume 
From Adaptive Biotechnologies
Via GlobeNewswire

Performance

YTD
+11.3%
+11.3%
1 Month
+1.7%
+1.7%
3 Month
-0.7%
-0.7%
6 Month
+71.8%
+71.8%
1 Year
+137.7%
+137.7%

More News

Read More
News headline image
The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Earnings Scheduled For November 5, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For August 5, 2025 ↗
Via Benzinga
News headline image
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys ↗
Via Benzinga
News headline image
Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Tesla To $300? Here Are 10 Top Analyst Forecasts For Monday ↗
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Adaptive Biotechnologies Through 4 Analysts ↗
Via Benzinga
News headline image
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday ↗
Via Benzinga
News headline image
Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies (NASDAQ:ADPT) Fits Minervini's Trend Template with Strong Growth Momentum ↗
Via Chartmill
News headline image
Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday ↗
Via The Motley Fool
News headline image
Adaptive (ADPT) Q2 Revenue Surges 36% ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics ↗
Via Benzinga
News headline image
Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025
From Adaptive Biotechnologies
Via GlobeNewswire

Frequently Asked Questions

Is Adaptive Biotechnologies Corporation - Common Stock publicly traded?
Yes, Adaptive Biotechnologies Corporation - Common Stock is publicly traded.
What exchange does Adaptive Biotechnologies Corporation - Common Stock trade on?
Adaptive Biotechnologies Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Adaptive Biotechnologies Corporation - Common Stock?
The ticker symbol for Adaptive Biotechnologies Corporation - Common Stock is ADPT on the Nasdaq Stock Market
What is the current price of Adaptive Biotechnologies Corporation - Common Stock?
The current price of Adaptive Biotechnologies Corporation - Common Stock is 17.71
When was Adaptive Biotechnologies Corporation - Common Stock last traded?
The last trade of Adaptive Biotechnologies Corporation - Common Stock was at 01/20/26 01:13 PM ET
What is the market capitalization of Adaptive Biotechnologies Corporation - Common Stock?
The market capitalization of Adaptive Biotechnologies Corporation - Common Stock is 2.56B
How many shares of Adaptive Biotechnologies Corporation - Common Stock are outstanding?
Adaptive Biotechnologies Corporation - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.